


FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICATION NO.: 10/719,493	ATTY. DOCKET NO.: C1039.70021US01
		FILING DATE: November 21, 2003	CONFIRMATION NO.: 3218
		APPLICANT: Arthur M. Krieg et al.	
		GROUP ART UNIT: 1643	EXAMINER: Parithosh K. Tungaturthi



U.S. PATENT DOCUMENTS

Examiner's Initials #	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
/AMG/		4,883,662		Stout	11-28-1989
↓		7,271,156	B2	Krieg et al.	07-18-2007
		7,354,711	B2	Macfarlane	04-08-2008
		7,402,572	B2	Krieg et al.	07-22-2008
		7,410,975	B2	Lipford et al.	08-12-2008
		2002-0151518	A1	Agrawal et al	10-17-2002
		2008-0009455	A9	Krieg et al.	01-10-2008
		2008-0026011	A1	Krieg et al.	01-31-2008
		2008-0031936	A1	Krieg et al.	02-07-2008
		2008-0045473	A1	Uhlmann et al.	02-21-2008
		2008-0113929	A1	Lipford et al.	05-15-2008
/AMG/		2008-0226649	A1	Schetter et al.	09-18-2008

FOREIGN PATENT DOCUMENTS

Examiner's Initials #	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
/AMG/		BAYEVER et al., Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: initial results of a phase I trial. Antisense Res Dev. 1993 Winter;3(4):383-90.	
↓		BRUNDA, Interleukin-12. J Leukoc Biol. 1994 Feb;55(2):280-8. Review.	
		DEBOER et al., Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancer. Cancer Immunol Immunother. 1992;34(5):306-12.	
/AMG/		FROST et al., MTP-PE in liposomes as a biological response modifier in the treatment of cancer: current status. Biotherapy. 1992;4(3):199-204. Review.	

EXAMINER: /Anne M. Gussow/	DATE CONSIDERED: 10/22/2008
-----------------------------------	------------------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/719,493	ATTY. DOCKET NO.: C1039.70021US01
				FILING DATE: November 21, 2003	CONFIRMATION NO.: 3218
				APPLICANT: Arthur M. Krieg et al.	
				GROUP ART UNIT: 1643	EXAMINER: Parithosh K. Tungaturthi
Sheet	2	of	2		

/AMG/		GU et al., Experimental studies on the immune regulation of fibroblast cell mediated interleukin- 6 gene therapy. J Med Col PLA. 1994; 9(1):50-4.	
		HAYASHI, A., Interferon-γ as a Marker for the Effective Cancer Immunotherapy with BCG-Cell Wall Skeleton. Proc Jap Acad. 1994 Dec 12; 70(10):205-209.	
		KRIEG, A.M., Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene. 2008 Jan 7;27(2):161-7. Review.	
		MAGLIANI et al., New immunotherapeutic strategies to control vaginal candidiasis. Trends Mol Med. 2002 Mar;8(3):121-6. Review.	
		MCDONALD et al., Defective cytostatic activity of pulmonary alveolar macrophages in primary lung cancer. Chest. 1990 Oct;98(4):881-5.	
		MUHLHAUSER et al., VEGF165 expressed by a replication-deficient recombinant adenovirus vector induces angiogenesis in vivo. Circ Res. 1995 Dec;77(6):1077-86.	
		PORGADOR et al., Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res. 1992 Jul 1;52(13):3679-86.	
		TANAKA et al., An antisense oligonucleotide complementary to a sequence in I gamma 2b increases gamma 2b germline transcripts, stimulates B cell DNA synthesis, and inhibits immunoglobulin secretion. J Exp Med. 1992 Feb 1;175(2):597-607.	
		TRINCHIERI et al., Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood. 1994 Dec 15;84(12):4008-27. Review.	
/AMG/		VICARI et al., Development of targeted toll-like receptor agonists for cancer therapy. PPO Focus. 2007; 1(2):1-15.	

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

EXAMINER: /Anne M. Gussow/	DATE CONSIDERED: 10/22/2008
-------------------------------	--------------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.